|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Denver, and Veterans Affairs Medical Center, Aurora, Colorado
Submitted May 21, 2009 ; accepted in final form August 6, 2009
Hyperphosphatemia associated with chronic kidney disease is one of the factors that can promote vascular calcification, and intestinal Pi absorption is one of the pharmacological targets that prevents it. The type II Na-Pi cotransporter NaPi-2b is the major transporter that mediates Pi reabsorption in the intestine. The potential role and regulation of other Na-Pi transporters remain unknown. We have identified expression of the type III Na-Pi cotransporter PiT-1 in the apical membrane of enterocytes. Na-Pi transport activity and NaPi-2b and PiT-1 proteins are mostly expressed in the duodenum and jejunum of rat small intestine; their expression is negligible in the ileum. In response to a chronic low-Pi diet, there is an adaptive response restricted to the jejunum, with increased brush border membrane (BBM) Na-Pi transport activity and NaPi-2b, but not PiT-1, protein and mRNA abundance. However, in rats acutely switched from a low- to a high-Pi diet, there is an increase in BBM Na-Pi transport activity in the duodenum that is associated with an increase in BBM NaPi-2b protein abundance. Acute adaptive upregulation is restricted to the duodenum and induces an increase in serum Pi that produces a transient postprandial hyperphosphatemia. Our study, therefore, indicates that Na-Pi transport activity and NaPi-2b protein expression are differentially regulated in the duodenum vs. the jejunum and that postprandial upregulation of NaPi-2b could be a potential target for treatment of hyperphosphatemia.
SLC34A2; PiT-1; hyperphosphatemia; chronic kidney disease; dietary Pi
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |